• Samih H Nasr, Samar M Said, Anthony M Valeri, Sanjeev Sethi, Mary E Fidler, Lynn D Cornell, Morie A Gertz, Angela Dispenzieri, Francis K Buadi, Julie A Vrana, Jason D Theis, Ahmet Dogan, and Nelson Leung.
• Department of Laboratory Medicine and Pathology, Mayo Clinic, Division of Anatomic Pathology, Hilton 10-20 200 First Street, SW, Rochester, Minnesota 55905, USA. nasr.samih@mayo.edu
• Kidney Int. 2013 Mar 1; 83 (3): 463-70.

AbstractLittle is known about the rare entities of heavy- and light-chain amyloidosis (AHL) and heavy-chain amyloidosis (AH). Here, we report the renal and hematological characteristics, pathology, and outcome of 16 patients with renal AH/AHL (5 with AH and 11 with AHL) and compare them with 202 patients with renal light-chain amyloidosis (AL) diagnosed during the same time period. All cases were diagnosed by kidney biopsy that showed Congo red-positive deposits. Amyloid typing was done by laser microdissection and mass spectrometry (LMD/MS) on 12 patients or by immunofluorescence on four patients. All patients with renal AH/AHL were Caucasians, with a male/female ratio of 2.2 and a median age at biopsy of 63 years. Compared with patients with renal AL, those with renal AH/AHL had less frequent concurrent cardiac involvement, higher likelihood of having circulating complete monoclonal immunoglobulin, lower sensitivity of fat pad biopsy and bone marrow biopsy for detecting amyloid, higher incidence of hematuria, and better patient survival. The hematological response to chemotherapy was comparable with renal AL. In 42% of patients, AH/AHL could not have been diagnosed without LMD/MS. Thus, renal AH/AHL is an uncommon and underrecognized form of amyloidosis, and its diagnosis is greatly enhanced by the use of LMD/MS for amyloid typing. The accurate histological diagnosis of renal AH/AHL and distinction from AL may have important clinical and prognostic implications.

24 keywords...

hide…